Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: We conducted this pooled analysis to investigate the impact of RECIST 1.1 on the selection of target lesions and classification of tumor response, in comparison with RECIST 1.0. Methods : We searched MEDLINE and EMBASE for articles with terms of RECIST 1.0 or RECIST 1.1. We looked into all abstracts and virtual meeting presentations from the conferences of ASCO and ESMO between 2009 and 2013.
Results: There were six articles in the literature comparing the clinical impacts of RECIST 1.0 and RECIST 1.1 in patients with metastatic cancer. A total of 359 patients were recruited from the six trials; 217 with non-small cell lung cancer, 61 with gastric cancer, 58 with colorectal cancer, and 23 with thyroid cancer. The number of target lesions by RECIST 1.1 was significantly lower than that by RECIST 1.0 (P<0.001). Because of new lymph node criteria, fourteen patients (3.1%) had no target lesions when adopting RECIST 1.1. RECIST 1.1 showed high concordance with RECIST 1.0 in the assessment of tumor responses (k = 0.903). Sixteen patients (4.8%) showed disagreement between the two criteria.
Conclusion: This pooled study demonstrated that RECIST 1.1 showed a highly concordant response assessment with RECIST 1.0 in patients with metastatic cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349880 | PMC |
| http://dx.doi.org/10.7150/jca.11316 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Since 2013, we have performed conversion surgery after hepatic arterial infusion chemotherapy (HAIC) for initially unresectable locally advanced hepatocellular carcinoma (LA-HCC).
Methods: Between 2013 and 2021, we assessed the surgical and oncological outcomes and pathological findings of patients with LA-HCC without extrahepatic spread (EHS) whose tumors converted from unresectable to resectable status with the New-FP regimen HAIC.
Results: We censored 153 patients with LA-HCC (Child-Pugh A, without EHS) indicated for HAIC.
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer.
J Immunother Cancer
September 2025
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Background: Peltopepimut-S is a therapeutic vaccine, which induces specific expansion of both CD4+helper and CD8+cytotoxic T-cells against human papillomavirus type 16 (HPV16) E6/E7 oncoproteins.
Patients And Methods: In a randomized phase 2 trial, we evaluated the efficacy and safety of peltopepimut-S plus cemiplimab compared with cemiplimab alone as first-line or second-line therapy in recurrent/metastatic HPV16-positive head and neck cancer. The primary efficacy endpoint was the objective response rate (ORR) by an independent review (Response Evaluation Criteria in Solid Tumors version 1.
Pre-treatment monocytic myeloid-derived suppressor cells as predictive biomarkers for immune checkpoint inhibitor response in clear cell renal cell carcinoma.
Front Immunol
September 2025
Department of Urology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Background: Immune checkpoint inhibitors (ICIs) are a cornerstone of systemic therapy for clear cell renal cell carcinoma (ccRCC), yet response rates remain variable and predictive biomarkers are lacking. This study aimed to determine whether baseline levels of myeloid-derived suppressor cells (MDSCs), especially monocytic (M-MDSC) and polymorphonuclear (PMN-MDSC) subtypes, could predict ICI response in ccRCC patients.
Methods: In this prospective cohort study, 20 ccRCC patients receiving ICI-based therapy for at least 3 months were enrolled.
Neoadjuvant Docetaxel-Carboplatin-Trastuzumab Therapy in HER2-Positive Breast Cancer: A Single-Center Experience from Vietnam.
Cancer Manag Res
August 2025
Department of Metabolic and Cardiovascular Disorders Treatment, National Hospital of Endocrinology, Hanoi, Vietnam.
Purpose: To evaluate the efficacy of neoadjuvant therapy and identify associated factors influencing treatment response in patients with HER2-positive breast cancer.
Subjects And Methods: A prospective, longitudinal study of 40 women with a mean age of 50.68 ± 10.
A magnetic resonance imaging radiomics approach predicts hepatocellular carcinoma response to stereotactic body radiation therapy.
Phys Imaging Radiat Oncol
July 2025
Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Background And Purpose: Predicting hepatocellular carcinoma (HCC) response to Stereotactic Body Radiation Therapy (SBRT) can be challenging. Here, we assessed the value of a radiomics-based machine learning (ML) approach for predicting HCC response to SBRT, using pre-treatment and early post-treatment magnetic resonance imaging (MRI).
Materials And Methods: This retrospective single-center study included 87 patients (M 67, mean age 65.